Squamous Cell Lung Carcinoma Overview
Learn About Squamous Cell Lung Carcinoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Virtua Medical Group, PA
Matthew Puc is a Thoracic Surgeon and a General Surgeon in Marlton, New Jersey. Dr. Puc and is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, ALK-Positive Non-Small Cell Lung Cancer, Endoscopy, and Pacemaker Implantation.
Cmc Dept Of Medicine Group PA
Christian Squillante is a Hematologist Oncology specialist and an Oncologist in Voorhees, New Jersey. Dr. Squillante and is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Squamous Cell Lung Carcinoma. Dr. Squillante is currently accepting new patients.
Cmc Dept Of Medicine Group PA
Alexandre Hageboutros is a Hematologist Oncology specialist and a Hematologist in Voorhees, New Jersey. Dr. Hageboutros and is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Lung Cancer. Dr. Hageboutros is currently accepting new patients.
Summary: Main objectives: To evaluate the benefit of SI-B001+ docetaxel on overall survival (OS) of bidotaxel. To evaluate the benefit of SI-B001+ Docetaxel over Docetaxel's progression-free survival (PFS) based assessment. Secondary objectives: To evaluate the investigator-evaluated progression-free survival (PFS) benefit of SI-B001+ Docetaxel against docetaxel; To evaluate the difference of objective res...
Summary: To evaluate the efficacy and safety of inhaled corticosteroids combined with bronchodilators and programmed death-ligand 1 (PD-L1) inhibitor plus platinum-based chemotherapy in patients with advanced lung squamous cell carcinoma complicated with chronic obstructive pulmonary disease (COPD)